Patents by Inventor Deniz Dalkara Mourot

Deniz Dalkara Mourot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220243291
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: December 14, 2021
    Publication date: August 4, 2022
    Inventors: David V. SCHAFFER, Ryan R. KLIMCZAK, James T. KOERBER, John G. FLANNERY, Deniz DALKARA MOUROT, Meike Visel, Leah C.T. BYRNE
  • Patent number: 11236402
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 1, 2022
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • Publication number: 20190218627
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 18, 2019
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C.T. Byrne
  • Patent number: 10214785
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: February 26, 2019
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • Patent number: 10202657
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: February 12, 2019
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • Patent number: 9856539
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: January 2, 2018
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • Patent number: 9587282
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: March 7, 2017
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • Publication number: 20160375151
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: August 23, 2016
    Publication date: December 29, 2016
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C.T. Byrne
  • Publication number: 20160376323
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: August 23, 2016
    Publication date: December 29, 2016
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C.T. Byrne
  • Patent number: 9458517
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: October 4, 2016
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • Publication number: 20160184394
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: November 11, 2015
    Publication date: June 30, 2016
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C.T. Byrne
  • Patent number: 9193956
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: November 24, 2015
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • Publication number: 20150232953
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: April 30, 2015
    Publication date: August 20, 2015
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C.T. Byrne
  • Publication number: 20150225702
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: January 27, 2015
    Publication date: August 13, 2015
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C.T. Byrne
  • Publication number: 20140364338
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: July 28, 2014
    Publication date: December 11, 2014
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C.T. Byrne
  • Publication number: 20140294771
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: April 20, 2012
    Publication date: October 2, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C.T. Byrne